Nurix Therapeutics posts Q3 2026 profit on $700 million Roche upfront payment
Nurix Therapeutics reported fiscal Q3 2026 revenue of $673.1 million, driven largely by a $653.2 million license payment from Roche after receiving a $700 million upfront fee. Net income jumped to $549.8 million and diluted GAAP EPS to $4.73. The company disclosed $1.1 billion in cash, cash equivalents and marketable securities, giving it a runway into the second half of 2029. It also dosed the first patient in a Phase 3 trial for bexobrutideg and discontinued development of NX‑2127.
Why it matters
The Roche payment lifts cash reserves to $1.1 billion, extending the company’s financial runway to 2029 (the company says). However, the revenue surge reflects a one‑time licensing fee rather than recurring sales, so investors should not treat the profit as sustainable.
Key facts
- 1Nurix received a $700 million upfront payment from Roche as part of the bexobrutideg collaboration. investingnews.com
- 2Cash, cash equivalents and marketable securities totaled $1.1 billion as of August 31 2026. investingnews.com
- 3Q3 2026 revenue was $673.1 million. tradingview.com
- 4License revenue from Roche accounted for $653.156 million of total revenue. sci-tech-today.com
- 5Net income for the quarter was $549.8 million. tradingview.com
- 6Diluted GAAP EPS was $4.73. seekingalpha.com
Summary written by AlphAI AI Desk from 13 of 13 sources. Not investment advice. Figures are as stated by the linked sources.